Haemoglobin fluctuations in patients on haemodialysis treated with ESAs: Clinical observations from two centres

Current Medical Research and Opinion

Volumn 25, Issue 12, 2009, Pages 2971-2976

  Roche, Alison ^a   Macdougall, Iain C ^a   Walker, Rowan G ^b  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Anaemia; Chronic kidney disease; Epoetin; Erythropoiesis stimulating agent; Haemoglobin; Renal dialysis

Indexed keywords

ANTIANEMIC AGENT; FERRITIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; AUSTRALIA; CLINICAL OBSERVATION; FEMALE; GEOGRAPHY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; UNITED KINGDOM;

AGED; CROSS-SECTIONAL STUDIES; DRUG DOSAGE CALCULATIONS; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES;

EID: 72549113461     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903350029     Document Type: Article

References (32)

1. Locatelli F, Aljama P, Bárány P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(Suppl 2):ii1-47 (Pubitemid 29401692)
2. Pollock C, McMahon L. The CARI guidelines. Biochemical and haematological targets guidelines. Haemoglobin. Nephrology (Carlton) 2005;10(Suppl 4):S108-15
3. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2007;50:471-530
4. Centers for Medicare & Medicaid Services 2004 Annual Report, End Stage Renal Disease Clinical Performance Measures Project. Department of Health and Human Services, Centers for Medicare & Medicaid Services, Office of Clinical Standards & Quality, Baltimore, Maryland, December 2004
5. Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44:94-111 (Pubitemid 38880932)
6. U.S. Renal Data System, USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2005
7. Li S, Collins AJ. Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. Kidney Int 2004;65:626-633 (Pubitemid 38130658)
8. Lacson Jr E, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis 2003;41:111-124 (Pubitemid 36043358)
9. Ebben JP, Gilbertson DT, Foley RN, et al. Hemoglobin level variability: associated with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 2006;1:1205-1210
10. Moeller S, Gioberge S, Brown G. ESRD patients in 2001: global overview of patients, treatment modalities and development trends. Nephrol Dial Transplant 2002;17:2071-2076
11. 27th ANZDATA Registry 2004 Report. Available at: http://www.anzdata.org. au/. [Accessed January 2008]
12. Hsu CY, Vittinghoff E, Lin F, et al. The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med 2004;141:95-101 (Pubitemid 38937830)
13. Roderick P, Davies R, Jones C, et al. Simulation model of renal replacement therapy: predicting future demand in England. Nephrol Dial Transplant 2004;19:692-701 (Pubitemid 38263132)
14. Ofsthun NJ, LaBrecque J, Keen M, et al. The association of mortality and hospitalization with hemoglobin (Hb) and missed dialysis treatments in stage 5 chronic kidney disease (CKD) patients with and without cardiac comorbidities. Nephrol Dial Transplant 2005;20(Suppl 5):v268
15. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-590 (Pubitemid 28385655)
16. Phrommintikul A, Haas SJ, Elsik M, et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007;369:381-388 (Pubitemid 46188479)
17. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005;68:1337-1343 (Pubitemid 43246455)
18. Berns JS, Elzein H, Lynn RI, et al. Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int 2003;64:1514-1521 (Pubitemid 37153820)
19. Collins AJ, Brenner RM, Ofman JJ, et al. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis 2005;46:481-488
20. Israni RK, Yang W, Joffe M, et al. A novel method of measuring haemoglobin variability in hemodialysis patients. J Am Soc Nephrol 2006;17:582A
21. Gunnel J, Yeun JY, Depner TA, et al. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999;33:63-72
22. Fishbane S. Recombinant human erythropoietin: has treatment reached its full potential? Semin Dial 2006;19:1-4
23. Macdougall IC. Optimizing the use of erythropoietic agents - pharmacokinetic and pharmacodynamic considerations. Nephrol Dial Transplant 2002;17:66-70
24. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001;16:3-13 (Pubitemid 32591159)
25. Halstenson CE, Macres M, Katz SA, et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 1991;50:702-712
26. Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999;10:2392-2395 (Pubitemid 29501473)
27. Allon M, Kleinman K, Walczyck M, et al. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Clin Pharmacol Ther 2002;72:546-555 (Pubitemid 36237726)
28. Jamal NM, Krzyzanski W, Cheung W, et al. Evaluation of epoetin alpha (rHuEPO) and darbepoetin alpha (DARB) on human burst-colony formation BFU-E) in culture. J Int Med Res 2006;34:42-51
29. Walker R, Pussell BA. Fluctuations in haemoglobin levels in haemodialysis patients receiving intravenous epoetin alfa or intravenous darbepoetin alfa. Nephrology 2007;12:448-451 (Pubitemid 47366636)
30. West RM, Harris K, Gilthorpe MS, et al. Functional data analysis applied to a randomized controlled clinical trial in hemodialysis patients describes the variability of patient responses in the control of renal anemia. J Am Soc Nephrol 2007;18:2371-2376 (Pubitemid 47203852)
31. Levin NW, Fishbane S, Valdés Cañedo F, et al. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007;370:1415-1421 (Pubitemid 47576167)
32. Sulowicz W, Locatelli F, Ryckelynck J-P, et al.; on behalf of the PROTOS Study Investigators. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007;2:637-646